A study found the higher dosage Copaxone halved the already low side effects of the regular dosage.
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) reports that a new Phase IIIb clinical trial of 40-mg Copaxone, which is administered three times a week, halved the side effects compared with 20-mg dosage, which is administered daily, for the treatment of multiple sclerosis. Copaxone is already known for having few side effects. Teva announced the results of the GLACIER study at the 66th annual American Academy of Neurology meeting in Philadelphia.
Teva added that, in addition to the convenience and advantages of the higher dosage Copaxone, compared with the regular dosage, the higher dosage also has medical advantages.
At the meeting, Teva also announced the results of studies of Laquinimod, its oral treatment for multiple sclerosis.
Published by Globes [online], Israel business news - www.globes-online.com - on May 1, 2014
© Copyright of Globes Publisher Itonut (1983) Ltd. 2014